WDA
TEVA icon

Wendell David Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Wendell David Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-9,025
Closed -$478K – 138
2014
Q1 		$478K Sell
9,025
-700
-7% -$32.4K 0.1% 115
2013
Q4 		$389K Sell
9,725
-9,450
-49% -$372K 0.09% 115
2013
Q3 		$729K Hold
19,175
– – 0.17% 97
2013
Q2 		$748K Buy
+19,175
New +$747K 0.19% 92

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Wendell David Associates's TEVA Position: Q2 2014 in Review

Wendell David Associates sold out of Teva Pharmaceuticals (TEVA) in Q2 2014, closing a stake of 9,025 shares — an estimated $478K sold.

Wendell David Associates first reported a position in TEVA in Q2 2013 and held it in 4 quarters. The position peaked at $748K in Q2 2013. 780 funds tracked by Wall St. Rank hold TEVA as of Q2 2014.

  • Wendell David Associates reported no remaining Teva Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Wendell David Associates sold 9,025 Teva Pharmaceuticals shares in Q2 2014, an estimated $478K.
  • Wendell David Associates first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Wendell David Associates's Teva Pharmaceuticals position peaked at $748K in Q2 2013.
  • 780 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2014.

Based on Wendell David Associates's 13F filing for Q2 2014, filed 24 Jul 2014.